Interaction between bone, the neuroendocrine system and metabolism

Limonard, E.J.

Citation for published version (APA):
Limonard, E. J. (2016). Interaction between bone, the neuroendocrine system and metabolism.
Clonidine increases bone resorption in humans

Eelkje J. Limonard, Ton Schoenmaker, Teun J. de Vries, Michael W. Tanck, Annemieke C. Heijboer, Erik Endert, Eric Fliers, Vincent Everts, Peter H. Bisschop

Osteoporosis International (2015), Accepted for publication
Abstract

Introduction Inhibition of sympathetic signaling to bone reduces bone resorption in rodents. It is uncertain whether a similar role for the sympathetic nervous system exists in humans. The sympathetic tone can be reduced by clonidine, which acts via alpha-2 adrenergic receptors in the brainstem. Our objective was to determine the effect of clonidine on bone turnover in humans.

Methods The acute effect of a single oral dose of 0.3 mg clonidine on serum bone turnover markers (C-terminal crosslinking telopeptides of collagen type I (CTx), a marker for bone resorption and procollagen type 1 N propeptide (P1NP), a marker for bone formation) was determined in a randomized crossover design in 12 healthy volunteers, aged 18-70 years. In addition, we assessed the effect of clonidine on the number of tartrate-resistant acid phosphatase-positive multinucleated cells (TRAcP+ MNCs) and bone resorption.

Results CTx concentrations increased after clonidine treatment compared to the control condition (p = 0.035). P1NP concentrations were not affected by clonidine (p = 0.520). In vitro, clonidine had no effect on the number of TRAcP+ MNCs (p = 0.513) or on bone resorption (p = 0.996).

Conclusions We demonstrated that clonidine increases bone resorption in humans in vivo. This effect does not appear to be mediated via a direct effect on the osteoclast.

Introduction

Bone remodeling is under control of the sympathetic nervous system (1-3). Knockout of the beta-2 adrenergic receptor (β2-AR) in osteoblasts resulted in a high bone mass phenotype (4). In line, administration of a β-blocker or β-agonist was shown to increase and decrease bone mass in mice, respectively (5-7). The role of the sympathetic nervous system in bone turnover was further supported by the high bone mass phenotype in mice with low sympathetic activity, due to dopamine β-hydroxylase deficiency (8). Recently, the role of the sympathetic nervous system in bone metabolism was extended by investigating mice with a double knockout of alpha-2A and alpha-2C adrenoceptor genes (9). Alpha-2 adrenoceptors are expressed in the brainstem, and when activated sympathetic activity is reduced. Consequently, knockout of alpha-2 adrenoceptors resulted in chronic sympathetic hyperactivity, indicated by increased norepinephrine release. Unexpectedly, these mice presented with a phenotype of high bone mass with increased bone formation and decreased bone resorption. It is uncertain whether human bone metabolism is also under control of the sympathetic nervous system. Epidemiological studies on the association between beta-blocker use and fracture risk showed inconclusive results, with β-blockers having positive, negative, or no effects on bone mass (10-22). Two recent meta-analyses indicate a small but significant risk reduction (15% and 17%, respectively) of any fracture in patients treated with beta-blockers.
Clonidine and human bone turnover (23, 24). This risk reduction was, however, associated with the use of beta-1 selective blockers, rather than non-selective beta-blockers. A case-control study comparing bone turnover in pheochromocytoma patients and controls showed that pheochromocytoma patients have increased bone resorption, which normalizes after adrenalectomy (25, 26). These findings support the concept of regulation of bone remodeling by the sympathetic nervous system in humans.

Pharmacological activation of alpha-2 adrenergic receptors in the brainstem by clonidine leads to a reduction in sympathetic tone. Clonidine is typically prescribed to treat hypertension and menopausal flushes. To study the effect of the sympathetic nervous system on bone in humans, we conducted a crossover study determining the acute effect of a single oral dose of 0.3 mg clonidine (a selective alpha-2 adrenergic receptor agonist) on bone turnover markers in 12 healthy subjects. We hypothesized that pharmacological alpha-2 adrenergic stimulation decreases C-terminal crosslinking telopeptides of collagen type I (CTx) and procollagen type 1 N propeptide (P1NP) concentrations, indicating decreased bone turnover. Unexpectedly, CTx concentrations increased after clonidine treatment compared to the control condition, indicating enhanced bone resorption. In view of these results, we further investigated whether the effects of clonidine are mediated via direct stimulation of alpha-2 adrenergic receptors on the osteoclast by determining the effect of clonidine on osteoclastogenesis and bone resorption in vitro.

**Subjects and Methods**

**In vivo effect of clonidine on bone formation and resorption**

*Subjects*

Twelve healthy female and male volunteers aged 18-70 years were recruited for this crossover study. Exclusion criteria for participation were 1] contraindications to clonidine, i.e., hypersensitivity, pulse rate < 50 per minute, use of antihypertensive drugs or drugs with negative chronotropic effects on the heart; 2] any medication or disease influencing bone turnover; 3] blood pressure < 110/70 mmHg; and 4] pregnancy. At baseline, we took a complete history and measured body weight, height, and blood pressure. A venous blood sample was drawn after an overnight fast to determine serum concentrations of calcium, albumin, phosphate, parathyroid hormone (PTH), 25-hydroxyvitamin D (25(OH)D), creatinine, and alkaline phosphatase.

*Study design*

This open-label crossover trial was performed at the Department of Endocrinology and Metabolism of the Academic Medical Center of the University of Amsterdam (AMC/UvA) in the Netherlands. All participating subjects were studied two times (clonidine and control) and served as their own control. The two study days were separated by a washout period of at least one week. Participants were randomly allocated to clonidine followed by no intervention or no intervention followed by clonidine using a computer-generated randomization list.
An antecubital vein of the arm was cannulated for all blood sampling. A baseline blood sample was drawn between 8:30 and 9:00 h to determine bone turnover markers (C-terminal crosslinking telopeptides of collagen type I [CTx] and procollagen type 1 N propeptide [P1NP]), normetanephrine, and creatinine concentrations in plasma or serum, after which participants received either a single oral dose of clonidine (a selective alpha-2 adrenoceptor agonist) 0.3 mg or no intervention at 9:00 h. Five blood samples were drawn during the following 6 h to determine bone turnover markers, normetanephrine, and creatinine concentrations. All blood samples were centrifuged within 30 min and stored at -20 °C until analysis. Participants were fasted throughout the experiment but were allowed to drink water. They were restricted to bed rest with minimal physical activity. During the experiment, blood pressure and heart rate were monitored every 15 min, with a Microlife® BP 3 AC1-1 automatic device. The study was approved by the Institutional Review Board of the Academic Medical Center (AMC) in Amsterdam and was carried out in compliance with the Helsinki Declaration. All subjects agreed to participate in the study and written informed consent was obtained from all participants. The trial was registered in the Netherlands Trial Register (NTR3762) before start of the study.

Measurements and analytical procedures

CTx, a marker of bone resorption, and P1NP, a marker of bone formation, were measured as bone turnover markers. CTx and P1NP concentrations were measured using an immun assay (Modular Analytics E 170; Roche Diagnostics Corporation, Indianapolis, IN; and Orion Diagnostica, Espoo, Finland, respectively), as described earlier (27). Plasma normetanephrine was determined by automated online solid phase extraction HPLC-tandem mass spectrometry as described by De Jong et al. (28). Serum creatinine concentrations were measured on a Hitachi Modular 8000 (C602 and C702) (Roche Diagnostics, Mannheim, Germany). Assays were performed in duplicate and samples from a single subject were assayed within the same analytical batch. Interassay coefficients of variation were as follows: CTx 3%, P1NP 8%, and normetanephrine 7.7%.

Effect of clonidine on osteoclast formation and activity

Cell isolation and culture

CD14+ monocytes were isolated from human buffy coats (Sanquin, Amsterdam, the Netherlands) obtained from healthy volunteers who provided written informed consent. Briefly, human buffy coats were diluted with phosphate-buffered saline (PBS) containing 1% citrate (1:1), and then spun down (800 g, 30 min, without brake) in Ficoll gradient solution. The interphase containing the peripheral blood mononuclear cells was collected and washed four times in 0.5% bovine serum albumin buffer (2 mM EDTA, phosphate-buffered saline) and then passed through a cell strainer (40 mm) (Greiner Bio-One) to ensure the recovery of a clean mononuclear cell population. Cells were counted using a Muse cell counter (Merck Millipore, Darmstadt, Germany) and incubated with CD14 antibody tagged microbeads (Miltenyi Biotec) (1 x 10^7 cells in 20 μL microbead solution) for 15 min at 4 °C and then sorted using a manual MACS magnetic cell sorter (Miltenyi Biotec) according to the manufacturer’s instructions. This
method is frequently used to isolate osteoclast precursors (29). The purity of the cells was confirmed to be 86% by flow cytometry (Accuri C6, Becton Dickinson) using a FITC-labeled CD14 antibody and mouse IgG2a isotype antibody (both Miltenyi Biotec) as control. Purified CD14+ cells were suspended in culture medium consisting of αMEM (Life Technologies) supplemented with 10% fetal calf serum (HyClone), 1% penicillin/streptomycin (Sigma-Aldrich), and 25 ng/mL macrophage colony-stimulating factor (M-CSF) (R&D systems). Bovine cortical bone slices of 650 μm thickness were soaked in a 96-well plate (Greiner Bio-One) with 100 μL culture medium for 2 h prior to seeding. Next, the medium was removed and 75 μL of medium containing 25 ng/mL M-CSF was added to the bone slices, upon which 75 μL of cell suspension containing 1.5 x 10⁵ cells was added. After three days of culturing with M-CSF, the medium composition was changed to 10 ng/mL M-CSF and 2 ng/mL receptor activator of nuclear factor kappa-B ligand (RANKL) (R&D Systems). All cultures were maintained at 37 °C, in a humidified atmosphere under 5% CO₂. Culture media were replaced every three to four days.

A time titration experiment was performed first, to determine the appropriate point in time to add clonidine. In this experiment, CD14+ cells were cultured for 28 days, with collection of samples for tartrate-resistant acid phosphatase (TRAcP) staining and bone resorption at days 7, 10, 14, 17, 21, 24, and 28. On day 17, wells were dissolved in RNA lysis buffer from the RNeasy Mini Kit (Qiagen, Hilden, Germany) and stored at -80 °C for RNA isolation to determine messenger RNA (mRNA) expression of osteoclast-related genes (tartrate-resistant acid phosphatase [TRAP], cathepsin K [CTSK], calcitonin receptor [CALCR] and dendritic-cell-specific transmembrane protein [DCSTAMP]) and of alpha-2 adrenergic receptor subtypes (ADRA2A, ADRA2B, ADRA2C). Based on the bone resorption results from this experiment (data not shown), we decided to add clonidine after 14 days of culturing.

In a separate experiment, clonidine (Sigma-Aldrich) was added to the culture medium after 14 days of culturing in increasing concentrations (10⁻⁹ M, 10⁻⁷ M, and 10⁻⁵ M). These concentrations were chosen based on peak plasma concentrations achieved after a single oral dose of clonidine 0.3 mg (30, 31) and concentrations used in a previous in vitro study using mouse osteoclasts (9). Wells containing the solvent (water) used for clonidine served as controls. After 14, 21, and 28 days of culturing, wells were washed with PBS and the cells were either fixed in 4% formaldehyde (used for TRAcP staining) or washed with water (used for bone resorption) and stored at 4 °C. All cultures were run at least in fivefold (for TRAcP staining), in tenfold (for bone resorption), and in sixfold (for RNA analysis).

TRAcP staining and cell count
Osteoclast-like cells were defined as multinucleated (three or more nuclei) tartrate-resistant acid phosphatase (TRAcP)-positive cells. After 14, 21, and 28 days of culturing TRAcP positivity was determined by enzyme histochemistry (Leukocyte Acid Phosphatase Staining Kit, Sigma-Aldrich). Nuclei were stained with diamidino-2-phenylindole dihydrochloride (DAPI). Per bone slice, the number of TRAcP-positive cells with three or more nuclei were counted at a x200 magnification. We considered multinucleated cells with three to five nuclei as small osteoclasts and multinucleated cells with more than five nuclei as large osteoclasts. The data were expressed as number of TRAcP+ multinucleated cells (MNCs) per square centimeter.
**Osteoclast resorption assay**
In order to evaluate osteoclast activity, resorption was analyzed after a culture period of 14, 21, and 28 days. Cells were lysed with demineralized water, after which bone slices were sonicated for 30 min in 10% ammonium to remove the cell remnants. Bone slices were then thoroughly washed with demineralized water and subsequently incubated in a 10% saturated alum (KAl(SO₄)₂·12H₂O) solution for 10 min. Finally, the bone slices were washed again with demineralized water and the resorption pits were stained with Coomassie brilliant blue. An entire bone slice was micrographed at a x200 magnification, using a digital camera, mounted on a light microscope (both from Leica, Wetzlar, Germany). We reconstructed the bone slices by merging the micrographs using Adobe Creative Suite Bridge (San Jose, CA, USA). The resorbed area was measured using Image Pro-Plus Software (Media Cybernetics, Silver Spring, MD, USA) and expressed as percentage of the total surface area.

**RNA isolation and qPCR**
Gene expression of osteoclast-related genes (TRAP, CTSK, CALCR, and DCSTAMP) and of alpha-2 adrenergic receptor subtypes (ADRA2A, ADRA2B, ADRA2C) was quantified by PCR at 17 days of culturing. Total RNA was extracted using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions. Reverse transcription of RNA was performed using the MBI Fermentas cDNA synthesis kit (Fermentas, Lithuania), using both the Oligo(dT)18 and the D(N)6 primers. Quantitative PCR (qPCR) was performed on the ABI PRISM 7000 Sequence Detection System as described previously (32). Primers were designed using the Primer Express software (version 2.0, Applied Biosystems, Foster City, CA, USA) (Table 1). To avoid amplification of genomic DNA, primers were designed such that each amplicon spanned at least one intron. The PCR reactions of the different amplicons had equal efficiencies as determined by serial dilutions of a calibrator sample. For the PCR analysis, porphobilinogen deaminase (PBGD) was used as housekeeping gene. Expression of this gene was not affected by the experimental conditions. Samples were normalized for the expression of PBGD by calculating the ΔCt (Ct gene of interest - Ct PBGD). Expression of the different genes is expressed as 2^(-ΔCt).

**Statistical analysis**
All data were analyzed using SPSS for Windows (version 21.0, SPSS Inc., Chicago, IL, USA). The mean and standard deviation (SD) or the median and interquartile range (IQR) are reported depending on the distribution. To determine the acute effect of a single oral dose of a selective alpha-2 adrenoceptor agonist versus no intervention on bone turnover and normetanephrine concentrations, we performed linear mixed model analysis with treatment and time as categorical fixed effects with correction for repeated measurements (AR1). The assumptions of the model were met (e.g., normally distributed residuals and homogeneous variances). For post hoc analysis of bone turnover marker and normetanephrine concentrations at the different time points, we used the paired t test. Comparisons of the number of TRAcP+ MNCs and percentage of resorbed bone area over time and between the different culture conditions at day 21 and day 28 were made with a Kruskal-Wallis test, followed by post-hoc comparison. All analyses were tested at the 0.05 level of significance.
### Table 1 qPCR primer sequences

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequence 5’ → 3’</th>
<th>Amplicon length (bp)</th>
<th>Ensembl Gene ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>PGBD</td>
<td>TgCgATTTggAAATCATgCTATgTC AACggCTTTTTCTCTCCAAATCTTTAgA</td>
<td>84</td>
<td>ENSG00000113721</td>
</tr>
<tr>
<td>TRAP</td>
<td>CACAATCTgCgAgTACCCTgCAAgAT CCCATAgTgAAAgCgCgAgATA</td>
<td>128</td>
<td>ENSG00000102575</td>
</tr>
<tr>
<td>CTSK</td>
<td>CCATAATgTgggACAggAgAgAgTT TgCATCAATgCCACAgAgA</td>
<td>149</td>
<td>ENSG00000143387</td>
</tr>
<tr>
<td>CALCR</td>
<td>gCATACCAAggAgAggTCCATAT ATACTCCAggCgTgTgTCAT</td>
<td>78</td>
<td>ENSG00000004948</td>
</tr>
<tr>
<td>DCSTAMP</td>
<td>ATTTTCTCAgTgAgCAAgCgTTTC AgAATCAtggATATAATCTTTgTgTTCCCTT</td>
<td>101</td>
<td>ENSG00000164935</td>
</tr>
<tr>
<td>ADRA2A</td>
<td>gCgAgATCAACgACCAAgAgT TCTggTAgATgCgCACgTAgA</td>
<td>101</td>
<td>ENSG00000150594</td>
</tr>
<tr>
<td>ADRA2B</td>
<td>CCCATggCTCCTTCCAgTT gAggCAgCggCggAAgT</td>
<td>100</td>
<td>ENSG00000222040</td>
</tr>
<tr>
<td>ADRA2C</td>
<td>gTgTggTgCggCggTgTAC CCTgCgTCACCgCACCgAgA</td>
<td>102</td>
<td>ENSG00000184160</td>
</tr>
</tbody>
</table>

For each gene, the first oligonucleotide sequence represents the forward primer and the second sequence, the reverse primer.
Results

In vivo experiment

Subject characteristics
We enrolled a total of 12 eligible study participants: four men, and five premenopausal and three postmenopausal women with a median age of 27 (IQR 32) years. All subjects had calcium, albumin, phosphate, PTH, and alkaline phosphatase concentrations within the reference range and normal kidney function. The median 25(OH)D concentration was 50 (IQR 24) nmol/L. None of the participants had a (family) history of bone diseases or fractures. Two subjects were current moderate smokers, and two were former smokers. None of the study subjects used > 2 units alcohol/day. Three premenopausal women used monophasic combined oral contraceptives. All had their tablet-free interval during the control day of the experiment. Two women had a regular menstrual cycle and were in the follicular phase during the intervention with clonidine. The other subjects did not use any medication.

Sympathetic nervous system and bone turnover markers
Stimulation of alpha-2 adrenoceptors by clonidine leads to a reduction in central sympathetic outflow and a resultant decrease in blood pressure, as well as a decrease in catecholamine release from sympathetic nerves. Plasma normetanephrine, a norepinephrine metabolite, concentrations can be regarded as a marker of sympathetic tone. As expected blood pressure (data not shown) and normetanephrine concentrations declined after clonidine treatment (Figure 1A). Baseline CTx (bone resorption) and P1NP (bone formation) concentrations were not different between the intervention and control days (p = 0.398 and p = 0.196, respectively). CTx was higher after clonidine compared to the control condition (time*intervention effect, p = 0.035) (Figure 1B). The effect was most evident 2 h (11:00) after clonidine administration, with CTx concentrations of 568.5±150.9 ng/L versus 474.9±143.1 ng/L in the control condition (p = 0.001). CTx concentrations remained significantly different throughout the remainder of the experiment (13:00, p = 0.005, and 15:00, p = 0.028). P1NP concentrations were not affected by clonidine (p = 0.520) (Figure 1C).
Figure 1 Normetanephrine (nmol/L) (A); C-terminal crosslinking telopeptides of collagen type I (CTx) (ng/L), a marker for bone resorption (B); and procollagen type 1 N propeptide (P1NP) (μg/L), a marker for bone formation (C) on the control (open dots) and intervention (closed dots) time points. Normetanephrine concentrations declined after clonidine treatment (time*intervention effect, p < 0.001). CTx was higher after clonidine compared to control (time*intervention effect, p = 0.035). P1NP concentrations were not affected by clonidine (time*intervention effect, p = 0.520). Data are expressed as mean±SEM. * p < 0.05; ** p < 0.01; *** p < 0.001.
**In vitro experiment**

*Formation of TRAcP+ MNCs and bone resorption*
Tartrate-resistant acid phosphatase-positive (TRAcP+) multinucleated cells (MNCs) were observed after 14 days of culturing (Figure 2A). The number of TRAcP+ MNCs increased in the course of the experiment, with a significant difference in the number of TRAcP+ MNCs (3-5 nuclei, 5+ nuclei, and total number) between 14 and 28 days of culturing (p = 0.003, p = 0.008, and p = 0.003). The total number of TRAcP+ MNCs increased from 103 (IQR 32) on day 14 to 649 (IQR 233) TRACP+ MNCs/cm² on day 28 of culturing (Figure 2B). Bone resorption pits could be visualised at 14 days of culturing (Figure 3A). In line with the formation of TRAcP+ MNCs, there was an increase in bone resorption from 1.1 (IQR 0.7) % to 6.9 (IQR 4.6) % of resorbed bone area between day 14 and day 28 of culturing (p = 0.001) (Figure 3B).

*mRNA expression*
At 17 days of culturing, osteoclast-like cells generated from human CD14+ cells expressed mRNA for all investigated osteoclast-related genes; TRAP, CTSK, CALCR and DCSTAMP (Ct values of 17.5-29.3 cycles), as well as the three alpha-2 adrenergic receptor subtypes (Ct values of 26.0-30.1 cycles).

*Effect of clonidine on osteoclast formation and osteoclast activity*
No significant effect of clonidine on the number of TRAcP+ MNCs (3-5 nuclei, 5+ nuclei, and total number) could be observed after 21 (p = 0.446, p = 0.380, and p = 0.693) and 28 days (p = 0.864, p = 0.454, and p = 0.513) of culturing (Figure 2B). The percentage of resorbed bone area did also not significantly differ between clonidine and control at 21 and 28 days of culturing (p = 0.789 and p = 0.996, respectively) (Figure 3B).
Figure 2 Representative example of tartrate-resistant acid phosphatase-positive (TRAcP+) multinucleated cell (MNC) (three nuclei or more) (arrows) formed from CD14+ monocytes isolated from human buffy coat at day 21. Scale bar = 50 μm (A). Formation of TRAcP+ MNCs at culture day 14, 21 and 28. Data are expressed as total number of TRAcP+ MNCs per square centimeter (mean±SEM). ** p < 0.01. CLO=clonidine (B).
Figure 3 Representative example of resorption pits (RP) (arrows) stained with Coomassie brilliant blue at day 21. Scale bar = 100 μm (A). Bone resorption at culture day 14, 21, and 28. Data are expressed as resorbed area as percentage of total surface area (mean±SEM). *** p < 0.001. CLO=clonidine (B).
**Discussion**

In this study, we demonstrated that a pharmacological decrease of the sympathetic nervous system tonus by clonidine, an alpha-2 adrenergic receptor agonist, increases CTx concentrations in humans in vivo, indicating enhanced bone resorption. We demonstrated expression of alpha-2 adrenoceptors by human osteoclast-like cells, but in vitro osteoclast formation and activity were not affected by clonidine.

Our data indicate that pharmacological inhibition of the sympathetic tone increases bone resorption in humans. This is compatible with recent findings in alpha-2A/C adrenergic receptor knockout mice, in which increased sympathetic activity was associated with decreased bone resorption and high bone mass (9). Both results oppose the general view that the sympathetic nervous system has a catabolic effect on the skeleton (4-8) and suggest that the observed changes in bone resorption are not sympathetically driven but mediated via direct stimulation of the alpha-2 adrenergic receptors on bone cells. To confirm this hypothesis we investigated the effect of clonidine on osteoclasts that were cultured in vitro. Osteoclast-like cells did express mRNA for all alpha-2 adrenergic subtypes, but osteoclast formation and activity were not affected by clonidine. These results are in line with previous observations. Arai et al. showed that treatment with clonidine does not affect the resorbing activity of human osteoclast-like cells generated from bone marrow obtained during artificial hip replacement surgery (33). In contrast, Fonseca et al. showed that osteoclasts generated from mouse bone marrow increased in number (51%) and activity (2.6-fold) in response to clonidine. The clonidine concentrations used were comparable to the concentrations in our experiment (9). A major difference between this study and ours is that we generated osteoclast-like cells from CD14+ cells selected from human buffy coats, while Fonseca et al. used osteoclasts that were cultured from mouse long bone marrow. Taken together these data strongly suggest that osteoclasts generated from CD14+ osteoclasts precursors of human origin do not respond to clonidine whereas those of mouse origin do.

An explanation for the conflicting results from our in vivo and in vitro experiments remains speculative. The clonidine concentrations in the in vitro experiment were based on in vivo peak plasma concentrations achieved after a single oral dose of 0.3 mg clonidine (30, 31) and on concentrations from a previous osteoclast culture experiment in rodents (9) and should therefore be sufficient. The osteoclast-like cells we generated fulfilled the functional criteria of mature osteoclasts, with positive TRAcP staining, formation of resorption pits on bone slices, and expression of osteoclast-related genes. It is, however, not certain that these osteoclast-like cells behave similar to osteoclasts in vivo. In vitro generated osteoclasts are formed by adding cytokines (M-CSF and RANKL) to the culture medium, whereas in vivo the interaction between precursors and cells of the osteoblastic lineage appears to be essential. Therefore, in volunteers, coupling between osteoclasts and other bone cells may have taken place, which is absent in our CD14+ cell cultures. It is therefore likely that clonidine increases bone resorption indirectly, via osteocytes and/or osteoblasts. Indeed, these cells have been reported to express the alpha-2 adrenergic receptor (33-36) and osteocytes have recently...
been recognized as a major player in skeletal activity (37). This would explain the observed discrepancy between the in vivo and in vitro effects of clonidine.

In vivo CTx concentrations increased after clonidine administration, indicating increased bone resorption. Clonidine also lowered arterial blood pressure, but not to such an extent that renal perfusion was compromised causing modified CTx clearance. Since plasma creatinine concentrations were not different between the two experimental conditions (data not shown), it is unlikely that the increase in CTx after clonidine is caused by reduced renal clearance of CTx. Other causes for the increase in CTx concentrations also need to be considered. A single oral dose of clonidine increases plasma growth hormone levels (38). However, in a recent study in obese premenopausal women, growth hormone administration for 6 months did not significantly increase CTx levels (39). Alpha-2 adrenergic receptor agonists have been reported to increase blood glucose levels (40), which might also influence bone turnover. We did not find a significant difference in glucose levels between the clonidine and control day (data not shown), making this explanation for the increase in CTx levels unlikely. Although we included in the in vivo experiment a heterogeneous group of only 12 subjects, we could demonstrate a robust effect of clonidine on bone resorption. This strengthens the biological relevance of the effect across different ages and sex. In addition, since baseline bone turnover marker concentrations were not significantly different between the intervention and control day, it is unlikely that other factors account for the changes in CTx concentrations we observed.

The clinical relevance of the increased bone resorption observed with clonidine needs to be considered. Clonidine is licensed for the treatment of hypertension, migraine, and postmenopausal vasomotor symptoms. Of note, postmenopausal women are already challenged with an increase in bone turnover. We did not investigate the long-term effect of clonidine use on bone turnover. However, based on the acute effect of a single oral dose of clonidine, prolonged treatment with clonidine could potentially aggravate the risk of developing osteoporosis. There are currently no studies on the association between long-term use of clonidine and bone mineral density or risk fracture.

In conclusion, an acute decrease in the sympathetic tone by clonidine increases bone resorption in humans in vivo. This effect does not appear to be mediated via direct stimulation of alpha-2 adrenergic receptors on the osteoclast.
References


